What Does a Gleason Pattern 4 Mean?

Gleason pattern 4 describes prostate cancer tissue that has lost the organized glandular structure seen in lower-grade disease, and its presence in a biopsy is one of the strongest signals that a tumor may behave aggressively. While Gleason pattern 3 cancer forms small, distinct, well-defined glands, pattern 4 cancer grows in fused, poorly formed, or sieve-like (cribriform) clusters where normal architecture has broken down. Whether pattern 4 shows up as the dominant or minor component of a Gleason score profoundly shapes prognosis and treatment decisions, but even within pattern 4 itself, not all subtypes carry the same risk.

How Gleason Pattern 4 Fits Into the Grading System

A Gleason score is built from two pattern numbers added together. The first number is the most common pattern the pathologist sees in the tissue; the second is the next most common. Patterns range from 1 to 5, but in modern practice patterns 1 and 2 are essentially never assigned on biopsy, so the meaningful range starts at 3. A score of 3+3=6 means all the visible cancer looks like pattern 3, the least aggressive form. Once pattern 4 enters the picture, the score jumps to at least 7, and that jump is clinically meaningful.

Since 2014, the International Society of Urological Pathology (ISUP) has recommended translating the old Gleason scores into five Grade Groups to make the system clearer for patients. A Gleason 3+4=7, where pattern 3 is dominant and pattern 4 is the minor component, becomes Grade Group 2. A Gleason 4+3=7, where pattern 4 is dominant, becomes Grade Group 3. Despite both adding up to 7, these are treated as meaningfully different diseases.

1Canadian Urological Association Journal. One is the new six: The International Society of Urological Pathology (ISUP) patient-focused approach to Gleason grading

Why the Order of the Numbers Matters So Much

If you have been told your Gleason score is 3+4 versus 4+3, the difference is not cosmetic. In one large study, men whose prostatectomy specimens showed 4+3 tumors had roughly three times the risk of dying from prostate cancer compared to men with 3+4 tumors.

2PubMed Central. Gleason Score and Lethal Prostate Cancer: Does 3 + 4 = 4 + 3?

Another study put hard timelines on it: the five-year risk of disease progression after surgery was about 15% for 3+4 tumors and roughly 40% for 4+3 tumors. Men with 4+3 disease were also more likely to develop metastases and had cancer that spread beyond the prostate at higher rates.

3PubMed. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy

A population-based cohort study confirmed this gap from a different angle. Men treated with surgery or radiation who had 4+3 tumors faced about twice the risk of recurrence or progression, and roughly three times the risk of dying from their cancer, compared to men with 3+4 tumors.

4PubMed Central. Differences in prostate cancer outcomes between cases with Gleason 4+3 and Gleason 3+4 tumors in a population-based cohort

In short, more pattern 4 means worse outcomes. But the picture gets even more nuanced when you look at what kind of pattern 4 is present.

The Subtypes of Pattern 4 Are Not Equal

Under the microscope, Gleason pattern 4 is not a single look. It encompasses at least four distinct growth patterns, and they do not all carry the same prognosis.

5PubMed Central. Clinical significance of subtypes of Gleason pattern 4 prostate cancer
  • Poorly formed glands: Small, irregular glands that lack clear central spaces. Pathologists generally agree on what these look like only when they appear in clusters of more than about ten glands that are not sitting right next to well-formed ones.
  • Fused glands: Glands that have merged together, losing their individual boundaries. Agreement among pathologists on identifying these is relatively low.
  • Glomeruloid structures: Ball-like tufts of cells that bulge into a gland space, resembling the tiny filters in a kidney. Research suggests these behave similarly to poorly formed and fused glands, not like the more dangerous cribriform pattern.
  • Cribriform glands: Large, sieve-like sheets of cancer cells perforated with holes, resembling a sponge. This is the subtype that has generated the most alarm in the research literature.

The distinction between these subtypes has real clinical weight. Men whose pattern 4 consisted only of simple glomeruloid structures had similar PSA levels, tumor extent, and surgical margin rates to men with only poorly formed and fused glands. But men who had invasive cribriform growth had significantly higher PSA, more advanced tumor stage, and more positive surgical margins.

6Modern Pathology. Clinicopathological characteristics of glomeruloid architecture in prostate cancer

Why Cribriform Pattern 4 Stands Out

Cribriform growth within pattern 4 has emerged as one of the single most important features a pathologist can report. Study after study links it to worse outcomes, even after accounting for other risk factors. In Gleason score 8 cancers, the presence of cribriform architecture independently doubled the risk of biochemical recurrence (a rise in PSA after treatment, suggesting the cancer is returning) and more than tripled the risk of metastasis.

7Modern Pathology. Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients

In Gleason 4+4 cancers treated with robotic surgery, the amount of cribriform growth mattered in a dose-dependent way. Men with no cribriform component had an 80% chance of being recurrence-free at three years. That dropped to about 63% if cribriform made up less than half the pattern 4, and to just 39% if cribriform comprised more than half.

8PubMed Central. Significance of the cribriform morphology area ratio for biochemical recurrence in Gleason score 4 + 4 prostate cancer patients following robot‐assisted radical prostatectomy

Cribriform growth also tends to travel with other worrying features. Men with cribriform pattern 4 in Gleason 7 cancers are more likely to have cancer extending beyond the prostate, positive surgical margins, and a companion finding called intraductal carcinoma, which is itself a marker of aggressive disease. When cribriform makes up more than 20% of the tumor, these adverse features become especially common.

9PubMed. Prognostic value of cribriform size, percentage, and intraductal carcinoma in Gleason score 7 prostate cancer with cribriform Gleason pattern 4

One study comparing many predictors in Grade Group 2 cancers found that the presence of cribriform or intraductal carcinoma outperformed both the percentage of pattern 4 and the presence of a small amount of pattern 5 in predicting recurrence. In their analysis, cribriform or intraductal carcinoma was the only independent predictor of biochemical recurrence, with roughly double the hazard.

10Histopathology. Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients

What Percentage of Pattern 4 Means for Your Risk

Beyond the subtype, the sheer amount of pattern 4 influences outcomes. Researchers have looked at the percentage of pattern 4 on biopsy as a way to stratify risk within Gleason 7 cancers. A study found that when pattern 4 on biopsy reached 20 to 30%, the odds of finding more aggressive disease in the surgical specimen jumped to roughly 2.5 times higher compared with having less than 10% pattern 4.

11PubMed Central. Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer

This percentage matters for treatment planning. A man whose biopsy shows 3+4 with 5% pattern 4 and no cribriform features has a very different risk profile from a man whose biopsy shows 3+4 with 40% pattern 4 and cribriform morphology. They carry the same Gleason score on paper, but one may be a candidate for active surveillance while the other likely needs definitive treatment. Many guidelines now encourage pathologists to report the percentage of pattern 4 explicitly, alongside noting whether cribriform growth is present.

How Reliable Is the Diagnosis?

One of the uncomfortable truths about Gleason grading is that pathologists do not always agree with each other, and pattern 4 is where some of the hardest judgment calls happen. Agreement on which Grade Group a case falls into is generally substantial, but agreement drops when pathologists are asked to identify cribriform growth or estimate the exact percentage of pattern 4. One study measuring inter-observer agreement found moderate agreement for cribriform and intraductal carcinoma and for percentage of pattern 4, compared to the stronger agreement for overall Grade Group.

12PubMed Central. Inter-observer variability of cribriform architecture and percent Gleason pattern 4 in prostate cancer: relation to clinical outcome

Estimating pattern 4 percentage on needle biopsies specifically showed that pathologists matched each other exactly about a third of the time, and agreed within a 10-percentage-point window about three quarters of the time. Small foci of pattern 4, involving less than 10% of the tissue, were the hardest to assess reliably.

13PubMed. Interobserver Reproducibility of Percent Gleason Pattern 4 in Prostatic Adenocarcinoma on Prostate Biopsies

This variability extends to the pattern 4 subtypes themselves. Poorly formed glands and fused glands are harder for pathologists to agree on than cribriform glands or glomeruloid structures.

5PubMed Central. Clinical significance of subtypes of Gleason pattern 4 prostate cancer

Consensus guidelines have tried to sharpen the definition. For example, a panel of urologic pathologists agreed that a cluster needs to be more than ten poorly formed glands, not sitting adjacent to well-formed ones, to count as pattern 4.

14PubMed. Diagnosis of “Poorly Formed Glands” Gleason Pattern 4 Prostatic Adenocarcinoma on Needle Biopsy: An Interobserver Reproducibility Study Among Urologic Pathologists With Recommendations

Upgrading From Biopsy to Surgery

A biopsy samples only tiny slivers of the prostate. The grade assigned on biopsy does not always match what pathologists find when they examine the entire prostate after surgery. Upgrading, where the surgical specimen reveals a higher Gleason score than the biopsy predicted, happens frequently enough that clinicians factor it into decision-making.

Several factors raise the odds of upgrading. A meta-analysis identified patient age, clinical tumor stage, the MRI-based PI-RADS score, the greatest percentage of cancer in any single biopsy core, and the number of positive cores as independent predictors.

15Clinical Genitourinary Cancer. What Does a Gleason Pattern 4 Mean? Smaller prostates, higher PSA density, and fewer biopsy cores also contribute to the risk of being under-graded at biopsy.

16Exploration of Targeted Anti-tumor Therapy. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy

MRI has helped close this gap. The PI-RADS score from a multiparametric MRI was found to be an independent predictor of upgrading, and incorporating it into prediction models significantly improved their accuracy.

17PubMed Central. Prediction of prostate cancer Gleason score upgrading from biopsy to radical prostatectomy using pre-biopsy multiparametric MRI PIRADS scoring system

MRI also proved adept at detecting the most dangerous pattern 4 subtypes. One study found that MRI picked up all index tumors, and on further analysis the presence of any pattern 4 and the presence of cribriform morphology were both tied to whether MRI could see a lesion in the first place.

18PubMed. Sensitivity of multiparametric MRI and targeted biopsy for detection of adverse pathologies (Cribriform gleason pattern 4 and intraductal carcinoma)

What Genomic Tests Add to the Picture

Pattern 4 is a visual diagnosis, made by a pathologist looking through a microscope. But molecular tests can add another dimension. Commercially available genomic classifiers measure gene activity in the tumor tissue and produce a risk score that is independent of what the pathologist sees.

One well-studied classifier, Decipher, uses broad RNA expression data to estimate the risk of metastasis. In Gleason 3+4 cancers, the presence of cribriform growth was associated with notably higher Decipher scores. Cases without cribriform had an average score of 0.41, cases with simple cribriform averaged 0.54, and cases with large cribriform reached 0.62. Large cribriform was also associated with a dramatically higher risk of biochemical recurrence, even after adjusting for stage and the percentage of pattern 4.

19PubMed Central. Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer

Other genomic tools exist for different clinical moments. The Prolaris test measures cell-cycle genes and predicts the risk of dying from prostate cancer over ten years under conservative management. The OncotypeDx Genomic Prostate Score estimates the risk of finding aggressive features at surgery. Each answers a slightly different question, but all aim to help distinguish indolent-looking cancers that are truly safe to watch from those that harbor hidden aggression.

20PubMed Central. Genomic testing for localized prostate cancer: where do we go from here?

At the DNA level, cribriform and intraductal cancers show a distinct pattern of genomic damage. They carry more chromosomal deletions and amplifications, including losses of tumor-suppressor genes like PTEN and gains of the cancer-promoting gene MYC.

21PubMed Central. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations

This genomic chaos helps explain why these tumors behave more aggressively, and it suggests that the pathologist’s microscopic impression and the molecular biology are telling the same story.

How AI Is Changing Pattern 4 Assessment

Because inter-observer variability is a known weakness in Gleason grading, artificial intelligence tools are being developed to assist pathologists. A deep learning system validated against subspecialist pathologists agreed with those experts on Gleason grade about 72% of the time, significantly outperforming the roughly 58% agreement rate of general pathologists. The improvement was most pronounced in Grade Group 2 cancers, exactly the territory where small differences in pattern 4 can shift treatment decisions. The AI’s error in estimating the amount of pattern 4 was roughly half that of general pathologists.

22JAMA Oncology. Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens

A more recent evaluation pitting multiple AI algorithms against each other and against pathologists found that the best commercial systems achieved very high agreement with expert consensus. The top-performing algorithms reached agreement scores on par with or above many individual pathologists.

23Modern Pathology. Evaluation of Artificial Intelligence-Based Gleason Grading Algorithms “in the Wild”

These tools are not replacing pathologists but are increasingly used as a second pair of eyes, particularly for standardizing the pattern 4 percentage and flagging cribriform architecture. Given how much rides on these details, reducing subjectivity is a meaningful step.

Treatment Decisions and Quality of Life

Whether pattern 4 is a minor or major component shapes the treatment conversation. A man with Grade Group 2 (3+4) disease, low percentage of pattern 4, and no cribriform features may be offered active surveillance, a strategy of close monitoring with biopsies and MRI at regular intervals, deferring treatment until there are signs of progression. As the proportion of pattern 4 rises, the case for definitive treatment with surgery or radiation strengthens.

For men with Grade Group 3 (4+3) disease, active surveillance is much less commonly offered. The combination of higher lethal risk and the possibility that the biopsy already underestimated the grade pushes most treatment discussions toward surgery, radiation, or a combination. When a man does receive treatment for intermediate-risk cancer, the choice between robotic surgery and radiation therapy involves trade-offs in quality of life. A study comparing the two after at least two years of follow-up found that robotic surgery patients reported better bowel function and overall satisfaction, while radiation patients initially reported better sexual function, though that advantage was offset by the hormonal side effects of the androgen-lowering drugs often paired with radiation. Urinary irritation was more common after radiation, while continence was comparable between the two approaches.

24PubMed Central. The comparison of post-treatment quality of life after at least two years of follow-up (≥ 24 months) between robotic radical prostatectomy and radiotherapy for intermediate-risk localized prostate cancer

When Prior Treatment Complicates the Grade

One scenario where the standard Gleason system falters is in men who have already received hormone therapy or radiation. Both of these treatments can drastically alter what the tissue looks like under a microscope, shrinking glands, distorting cell shapes, and sometimes making it impossible to tell residual cancer from treatment-damaged normal tissue. In these cases, assigning a reliable Gleason pattern becomes difficult or sometimes inappropriate altogether.

25PubMed Central. Treatment-related changes in the prostate: past, present and future therapies

This is worth knowing if you receive a pathology report after neoadjuvant hormone therapy or salvage radiation. A Gleason score in that context may carry a different meaning than the same number on an untreated biopsy. Pathologists sometimes note that grading is unreliable due to treatment effect, and clinicians rely more heavily on other markers, like PSA trends and imaging, in these situations.

Glomeruloid Structures and Their Uncertain Place

Glomeruloid structures occupy an interesting gray zone. They were not part of the original Gleason system and were incorporated into pattern 4 relatively recently, based partly on the observation that they often appear alongside cribriform cancer and may represent an early stage of cribriform development. One study found that roughly 80% of biopsy cores with glomeruloid structures also contained pattern 4 cancer, and pathologists could sometimes trace a visible transition from small glomeruloid tufts into full cribriform sheets.

26PubMed Central. Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy

Yet when researchers compared outcomes, simple glomeruloid structures behaved much more like poorly formed and fused glands than like cribriform disease. Men with only simple glomeruloid growth had significantly lower PSA, less advanced stage, and fewer positive margins than men with cribriform cancer.

6Modern Pathology. Clinicopathological characteristics of glomeruloid architecture in prostate cancer

This has led some researchers to question whether simple glomeruloid structures should carry the same weight as cribriform when making treatment decisions. Currently, they are all classified as pattern 4, but the evidence suggests they sit at the less dangerous end of the spectrum. Future updates to the grading system may eventually treat them differently.